Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,342.00
Bid: 12,340.00
Ask: 12,344.00
Change: 78.00 (0.64%)
Spread: 4.00 (0.032%)
Open: 12,268.00
High: 12,388.00
Low: 12,256.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-France was right to decide against new national lockdown -health minister

Tue, 09th Feb 2021 09:19

(Adds quotes, details)

By Dominique Vidalon

PARIS, Feb 9 (Reuters) - The COVID-19 situation in France is
currently stable and the government was right to have decided
against imposing a new national lockdown, Health Minister
Olivier Veran said on Tuesday

Veran also told France Info radio "it is possible and indeed
preferable" that France would not have to be locked down again.

"For three weeks we have had (on average) 20,000 new cases
per day and 3,000-3,200 patients in intensive care units. It's
stable but high...It does not call for national lockdown
measures," Veran said.

The number of people in France who have died from COVID-19
infections rose by 458 on Monday to 79,423 - the seventh-highest
death toll globally.

Unlike some of its neighbours, France has refrained from
imposing a third national lockdown, hoping that a curfew in
place since Dec. 15 and a vaccination programme that has now
given shots to more than 2 million people will be enough to rein
in the spread of the disease.

Veran said he expected that between 3.5 milllion and 4
million people in France would have received their first dose of
a COVID-19 vaccine by the end of February.

Some health officials have however warned about the strain
being placed on the hospital system and the impact of more
contagious variants of the coronavirus.

Veran reiterated that the AstraZeneca's vaccine was
efficient against 99% of the COVID-19 strains in France but that
France was considering using vaccines other than AstraZeneca's
vaccine for overseas territories.

"We are monitoring the progression of the South African
variant, notably in {the French island of) Mayotte. We are
considering increasing the protection of health workers in
overseas territories," he said

South Africa decided to put on hold use of AstraZeneca's
COVID-19 shot in its vaccination programme after data showed it
gave minimal protection against mild-to-moderate infection
caused by the country's dominant coronavirus variant.

Health authorities reported 4,317 new confirmed COVID-19
cases in France on Monday, down from 19,715 on Sunday and 4,347
last Monday. The number of people in hospital with the virus
went up by 343, to 28,037.

(Reporting by Dominique Vidalon, Editing by Gareth Jones and
Angus MacSwan)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.